SC
TVRD

Sculptor Capital’s Tvardi Therapeutics TVRD Stock Holding History

Sculptor Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-972
Closed -$479K – 207
2017
Q3 		$479K Hold
972
– – ﹤0.01% 293
2017
Q2 		$539K Buy
972
+650
+202% +$412K ﹤0.01% 273
2017
Q1 		$213K Buy
+322
New +$172K ﹤0.01% 286

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sculptor Capital's TVRD Position: Q4 2017 in Review

Sculptor Capital sold out of Tvardi Therapeutics (TVRD) in Q4 2017, closing a stake of 972 shares — an estimated $479K sold.

Sculptor Capital first reported a position in TVRD in Q1 2017 and held it in 2 quarters. The position peaked at $566K in Q1 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q4 2017.

  • Sculptor Capital reported no remaining Tvardi Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Sculptor Capital sold 972 Tvardi Therapeutics shares in Q4 2017, an estimated $479K.
  • Sculptor Capital first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 2 quarters.
  • Sculptor Capital's Tvardi Therapeutics position peaked at $566K in Q1 2017.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2017.

Based on Sculptor Capital's 13F filing for Q4 2017, filed 13 Feb 2018.